Re­searchers plot a course in­to PhI­II af­ter an­oth­er Alzheimer’s drug flunks a key test

An­oth­er big Alzheimer’s drug study has foundered in the clin­ic, but it’s be­ing po­si­tioned for Phase III in any case.

This time the fail­ure be­longs to Toya­ma Chem­i­cal, a sub­sidiary of Fu­ji­film, which wound up re­cruit­ing close to 500 pa­tients with a mild-to-mod­er­ate form of the dis­ease for the tri­al.

Ac­cord­ing to the com­pa­ny, the drug failed the pri­ma­ry end­point and the sec­on­daries, prov­ing un­able to do any bet­ter than a place­bo in im­prov­ing cog­ni­tion or func­tion. But, re­searchers say they tracked a ben­e­fit in a key bio­mark­er for tau on the high dose while spot­ting an im­prove­ment among ear­li­er-stage pa­tients in a post hoc analy­sis of the da­ta.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.